These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 36752642)
1. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. Wang Q; Shen X; Chen G; Du J Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642 [TBL] [Abstract][Full Text] [Related]
2. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142 [TBL] [Abstract][Full Text] [Related]
3. Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies. Yang C; Zhao L; Lin Y; Wang S; Ye Y; Shen Z Crit Rev Oncol Hematol; 2024 Aug; 200():104204. PubMed ID: 37984588 [TBL] [Abstract][Full Text] [Related]
4. Application of immune checkpoint inhibitors in colorectal cancer. Wang L; Huang C Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640 [TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Cohen R; Rousseau B; Vidal J; Colle R; Diaz LA; André T Target Oncol; 2020 Feb; 15(1):11-24. PubMed ID: 31786718 [TBL] [Abstract][Full Text] [Related]
7. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582 [TBL] [Abstract][Full Text] [Related]
8. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494 [TBL] [Abstract][Full Text] [Related]
9. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635 [TBL] [Abstract][Full Text] [Related]
10. Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability. Borelli B; Antoniotti C; Carullo M; Germani MM; Conca V; Masi G Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291761 [TBL] [Abstract][Full Text] [Related]
11. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer. Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G Front Immunol; 2023; 14():1298524. PubMed ID: 38187388 [TBL] [Abstract][Full Text] [Related]
12. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. Almquist DR; Ahn DH; Bekaii-Saab TS BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441 [TBL] [Abstract][Full Text] [Related]
13. Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era? Matteucci L; Bittoni A; Gallo G; Ridolfi L; Passardi A Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958363 [TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. André T; Cohen R; Salem ME Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834 [TBL] [Abstract][Full Text] [Related]
17. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636 [TBL] [Abstract][Full Text] [Related]
18. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective. Liu N; Shan F; Ma M Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568 [TBL] [Abstract][Full Text] [Related]
19. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability. Ratovomanana T; Nicolle R; Cohen R; Diehl A; Siret A; Letourneur Q; Buhard O; Perrier A; Guillerm E; Coulet F; Cervera P; Benusiglio P; Labrèche K; Colle R; Collura A; Despras E; Le Rouzic P; Renaud F; Cros J; Alentorn A; Touat M; Ayadi M; Bourgoin P; Prunier C; Tournigand C; Fouchardière C; Tougeron D; Jonchère V; Bennouna J; de Reynies A; Fléjou JF; Svrcek M; André T; Duval A Ann Oncol; 2023 Aug; 34(8):703-713. PubMed ID: 37269904 [TBL] [Abstract][Full Text] [Related]